Harnessing the power of the endocannabinoid system.

At OCT, we are developing safe and effective prescription medicines to treat serious and life-threatening human diseases and conditions.


Find out more

Therapeutic Areas

OCT is focused on drug development for indications in oncology, pain, immunology and neurology.


Find out more

Our Approach

OCT utilises a range of compounds in drug development, including proprietary cannabinoid derivatives, unmodified phytocannabinoids and terpenes, and in-licensed compounds that target the endocannabinoid system. By utilising a range of inputs, OCT is creating a drug development portfolio that maximises the therapeutic potential of cannabinoids, balances long-term market value, and ensures intellectual property protection across all activities.

Find out more

Recent news, reports & resources


All News

  • An interview with Neil Mahapatra

    08 January 2019 The Times Magazine
  • High life: the start-up hoping to unlock the secrets of medical cannabis

    09 August 2018 Evening Standard
  • Snoop Dogg’s VC and Imperial Tobacco Investing in Cannabis Biotech

    29 June 2018 High Times

Get in touch

Oxford Cannabinoid Technologies Ltd
1 Maddox Street
London W1S 2PZ

Find us on a map